← Eichor
Study identifier: NCT05677971 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Condition: Alpha1-Antitrypsin Deficiency  ·  Sponsor: Takeda

PhasePhase 3
Planned participants160
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.

This description comes directly from the study's public registry record.

Talk to the study team

Takeda Contact  ·  1-877-825-3327  ·  medinfoUS@takeda.com

Always discuss trial participation with your own doctor first.

Locations (89)

University of Alabama at BirminghamBirmingham, Alabama, United StatesRecruiting
St. Joseph's Hospital and Medical CenterPhoenix, Arizona, United StatesRecruiting
Mayo ClinicPhoenix, Arizona, United StatesRecruiting
University of Arizona Thomas D. Boyer Liver InstituteTucson, Arizona, United StatesWithdrawn
Gastroenterology & Liver InstituteEscondido, California, United StatesWithdrawn
University of California San Diego, Altman Clinical and Translational InstituteLa Jolla, California, United StatesRecruiting
UCLA Pulmonary and Critical CareLos Angeles, California, United StatesRecruiting
Stanford UniversityPalo Alto, California, United StatesRecruiting
University of California Benioff Children's HospitalSan Francisco, California, United StatesRecruiting
Peak Gastroenterology Associates, PCColorado Springs, Colorado, United StatesRecruiting
University of FloridaGainesville, Florida, United StatesRecruiting
Schiff Center for Liver Diseases/University of MiamiMiami, Florida, United StatesRecruiting

+ 77 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05677971